Skip to main content

Table 2 Correlations of YAP1 protein expression and clinical and molecular parameters of the randomised cohort (n=500)

From: Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

 

All patients, n= 500

 

ER+patients, n=324

 
 

YAP1 intensity, n=324

 

YAP1 intensity, n=213

 
 

Absent

Weak

Intermediate

Strong

p-value

Absent

Weak

Intermediate

Strong

p-value

 

n (%)

n (%)

n (%)

n (%)

 

n (%)

n (%)

n (%)

n (%)

 

Variable

28 (9)

130 (40)

128 (39)

38 (12)

 

21 (10)

95 (45)

79 (37)

18 (8)

 

NHG

          

I

0

10 (8)

11 (9)

5 (13)

 

0

10 (11)

11 (14)

5 (28)

 

II

13 (48)

55 (44)

56 (45)

10 (27)

 

12 (57)

48 (50)

51 (65)

9 (50)

 

III

14 (52)

60 (48)

57 (46)

22 (60)

0.932a

9 (43)

37 (39)

16 (21)

4 (22)

0.001a

Lymph node status

          

Negative

7 (25)

35 (27)

34 (27)

15 (41)

 

5 (24)

25 (26)

19 (24)

5 (29)

 

Positive

21 (75)

94 (73)

94 (73)

22 (59)

0.285b

16 (76)

70 (74)

60 (76)

12 (71)

0.971b

Tumour size

          

<20 mm

12 (44)

43 (33)

46 (36)

13 (34)

 

10 (50)

35 (37)

33 (42)

6 (33)

 

≥20 mm

15 (56)

87 (67)

82 (64)

25 (66)

0.815b

10 (50)

60 (63)

46 (58)

12 (67)

0.757b

ERα

          

<10%

4 (16)

33 (26)

46 (37)

20 (53)

 

-

-

-

-

 

≥10%

21 (84)

95 (74)

79 (63)

18 (47)

<0.001b

-

-

-

-

 

PgR

          

<10%

6 (24)

35 (29)

47 (39)

20 (56)

 

1 (5)

6 (7)

4 (5)

0

 

≥10%

19 (76)

86 (71)

75 (61)

16 (44)

0.002b

18 (95)

84 (93)

73 (95)

16 (100)

0.464b

Ki-67 fraction (%)

          

0-10

12 (48)

48 (40)

53 (45)

10 (29)

 

9 (47)

37 (42)

47 (64)

9 (56)

 

11-25

7 (28)

38 (32)

34 (29)

7 (20)

 

6 (32)

30 (34)

20 (27)

3 (19)

 

26-100

6 (24)

34 (28)

31 (26)

18 (51)

0.198a

4 (21)

21 (24)

6 (8)

4 (25)

0.016a

Cyclin D1 intensity

          

absent/weak

8 (31)

67 (53)

81 (67)

29 (76)

 

3 (14)

39 (42)

40 (51)

9 (50)

 

intermediate/strong

18 (69)

59 (47)

40 (33)

9 (24)

<0.001b

18 (86)

54 (58)

38 (49)

9 (50)

0.010b

CCND1 amplification

          

No

8 (44)

69 (84)

75 (89)

24 (96)

 

5 (36)

48 (80)

47 (84)

12 (92)

 

Yes

10 (56)

13 (16)

9 (11)

1 (4)

<0.001b

9 (64)

12 (20)

9 (16)

1 (8)

0.003b

  1. NHG=Nottingham histological grade, ERα=estrogen receptor, PgR=progesterone receptor.
  2. aSpearman´s rank correlation.
  3. bMann-Whitney U test.